Objective: The GOLD guidelines suggest that the presence of a post-bronchodilator forced expiratory volume in one second (FEV 1 ) Ͻ 80% of the predicted value in combination with a FEV 1 /forced vital capacity (FVC) Ͻ 70% confi rms the diagnosis of COPD. Limited data exist regarding the accuracy of these criteria to distinguish between COPD and asthma. The aim of this study therefore was to investigate the diagnostic value of post-bronchodilator lung function parameters in obstructive lung disease.
Introduction
COPD and asthma are common conditions and their worldwide prevalence is expected to increase over the next twenty years (Murray and Lopez 1997) . Although the two diseases share many clinical features, there are important clinical and pathological differences infl uencing choice of medication and long-term aims of management (Jeffrey 1998; Celli 2000; Fabri et al 2003) .
The degree of reversibility following bronchodilator administration has played a pivotal role in the evaluation of obstructive lung disease, thereby infl uencing drug choice and patterns of care (Dow 1999) . In addition to the clinical importance, bronchodilator testing can have regulatory importance as European regulators now require that COPD patients included in clinical trials meet the ERS defi nition of irreversible disease . Signifi cant reversibility is denoted by the American Thoracic Society (ATS) as a change of Ͼ12% of the baseline forced expiratory volume in one second (FEV 1 ) if this also exceeds 200 mL, while the European Respiratory Society (ERS) recommends a change of Ͼ9% of the predicted FEV 1 (American Thoracic Society 1991; Quanjer et al 1993) . The numerous ways of expressing BDR have been challenged repeatedly (Weir and Burge 1991; Brand et al 1992; Dompeling et al 1992) . Although historically used to diagnose asthma, none of these current defi nitions are sensitive or suffi ciently specifi c to differentiate asthma from COPD purely on spirometric grounds (Meslier et al 1989; Bran et al 1992; Quedrelli et al 1999b) .
The GOLD guidelines suggest that the diagnosis of COPD should be confi rmed by spirometry. The presence of a post-bronchodilator FEV 1 Ͻ 80% of the predicted value in combination with a FEV 1 /FVC Ͻ 70% confi rms the presence of airfl ow limitation that is not fully reversible (Pauwels et al 2001) . The usefulness of these post-bronchodilator spirometric variables as diagnostic criteria in BDR testing has to our knowledge not been assessed systematically in patients with obstructive lung disease.
The aim of our study, therefore, was to investigate the accuracy of a number of spirometric criteria used to express the BDR and assess how well they are able to distinguish between COPD and asthma in our study population. We hypothesized that the post-bronchodilator FEV 1 Ͻ 80% of the predicted in combination with a FEV 1 /FVC ratio of Ͻ 70% would be more sensitive and specifi c to distinguish COPD from asthma than the use of ATS and ERS BDR criteria in moderately severe obstructive lung disease.
Methods Subjects
Consecutive subjects with airways obstruction, meeting inclusion criteria as specifi ed below, were prospectively recruited. All participants had to be able to perform technically acceptable pulmonary function tests. Medical histories, including specifi c respiratory symptoms, were obtained in a standardized manner. Inclusion criteria for the COPD group were a smoking history of more than ten pack years, associated with chronic cough and/or sputum production with an onset of symptoms after 40 years of age. An exclusion criterion for the COPD group was a history of asthma. The asthma group had to be older than 40 years of age with recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. In addition, these subjects had to be ex-or nonsmokers with a less than ten pack year history. All patients had to be clinically stable with no respiratory exacerbations for six weeks prior to inclusion in the study and no changes in chronic medication during this period. Respiratory exacerbations were defi ned as an increase in breathlessness, sputum volume or sputum purulence from baseline requiring treatment with prednisone and/or antibiotics.
To ensure comparable baseline characteristics, we included only patients with a pre-bronchodilator FEV 1 % predicted of between 40% and 70% as well as a FEV 1 /FVC ratio between 45% and 65%, as the population of moderately severe obstructive lung disease poses the greatest challenge in differentiating COPD from asthma.
Study design
All subjects signed written informed consent for participation in the study. The local ethics committee approved the study. Bronchodilator treatment was withdrawn prior to pulmonary function testing according to standard practice (immediate release theophylline: 24 hours, long acting β 2 -agonist: 12 hours, short acting β 2 -agonist: 6 hours and short acting anticholinergic: 8 hours).
Procedures
A qualifi ed pulmonary technologist conducted maximal in-and expiratory fl ow volume curves with subjects seated before ('pre') and after ('post') administration of 400 μg salbutamol. The medication was given via a metered dose inhaler with a large volume spacer (Volumatic, GlaxoSmithKline). ATS guidelines (1994) were adhered to concerning spirometric assessments, calibration and equipment maintenance. All pulmonary function measurements were made using a Jaeger Masterscope 4.0 spirometer (Würzburg, Germany). Predicted normal values were calculated as laid down by the European Community for Coal and Steel (ECCS). For analysis, the best FEV 1 and forced vital capacity (FVC) were chosen regardless of the curve. The 'best test' curve was selected from the largest sum of FEV 1 and FVC. All other lung function parameters selected for analysis were taken from the 'best test' curve.
Evaluation of bronchodilator response
Bronchodilator responsiveness (BDR) was calculated according to the following three criteria: 1) FEV 1 postbronchodilator Ͻ80% predicted and FEV 1 /FVC ratio Ͻ 70%, 2) FEV 1 change from initial (FEV 1 %Δinit: post FEV 1 -pre FEV 1 /pre FEV 1 × 100) less than 12% and FEV 1 absolute change (FEV 1 abs Δ: post FEV 1 -pre FEV 1 ) less than 200 mL (according to ATS guidelines) (American Thoracic Society 1991) and 3) FEV 1 change from predicted (FEV 1 %Δpred: post FEV 1 -pre FEV 1 /predicted FEV 1 × 100) less than 9% (according to ERS guidelines) (Quanjer et al 1993) .
Data analysis
Results are presented as means + standard error of mean. A p value of Ͻ 0.05 was considered signifi cant. Descriptive group data were compared using the unpaired student t-test. Differences among the groups were evaluated using analysis of variance (ANOVA). The sensitivity and specifi city as well as the predictive values and accuracy of a BDR to salbutamol in distinguishing patients with COPD and asthma were calculated for the three criteria as outlined above.
Results

Subject characteristics
104 patients with COPD and 127 patients with asthma were evaluated consecutively. 22 COPD and 21 asthma patients with a baseline FEV 1 of 55.7% + 7.6%, and 59.3% + 8.4% predicted respectively met the inclusion criteria and were included for further analyses.
Subject characteristics are outlined in Table 1 . The COPD and asthma groups had comparable baseline pre-bronchodilator pulmonary function tests and demographics.
All subjects were on short acting β 2 -agonist therapy. 9 (41%) COPD patients were on inhaled or oral corticosteroids, 5 (23%) were on long acting β 2 -agonist therapy and 8 (36%) were on theophylline. All asthmatic patients were on inhaled steroids. No asthmatic patient was on oral steroids, theophylline or long acting β 2 -agonist therapy. Subgroup analysis showed that corticosteroid treatment did not signifi cantly infl uence bronchodilator response within the COPD group (p Ͻ 0.07, data not shown).
Bronchodilator responses
Spirometric changes in response to salbutamol are shown in Table 2 . After salbutamol inhalation there was a statistically signifi cant increase of all fl ow volume curve parameters in both groups. The mean responses were signifi cantly greater for the asthma group for all the FEV 1 criteria ( Table 2 ). The absolute change in FVC after bronchodilator administration was significantly greater in the asthma subjects in comparison to the COPD group ( Table 2) . The FEF 50 showed a signifi cant response to salbutamol in the asthma patients, but not in the subjects with COPD ( Table 2 ). The pre-and post-bronchodilator FEV 1 /FVC ratio remained almost the same in the COPD group, whereas in comparison the ratio increased signifi cantly (p = 0.003) in the asthma group (Figure 1) . The post bronchodilator FEV 1 % predicted was signifi cantly (p = 0.0002) lower in the COPD group (Figure 1 ). All COPD and 13 (62%) of asthma patients fulfi lled the fi rst tested BDR criteria (FEV 1 post-bronchodilator Ͻ80% predicted and FEV 1 /FVC ratio Ͻ70%). 12 (55%) COPD and 4 (19%) Asthma patients had a positive response according to the second criteria of a BDR Ͻ 12% and FEV 1 absolute change Ͻ200 mL. The third BDR criteria, FEV 1 change from predicted Ͻ9%, was fulfi lled in 13 (59%) COPD and 5 (24%) asthma patients. There was a signifi cant difference between the two groups in the FEV 1 bronchodilator response when expressed as a percentage of the initial value (p = 0.001) as well as for the change from predicted criteria ( p = 0.0003) (Figure 2 ). The sensitivity, specificity, predictive values and accuracy of diagnosing COPD for each of the three BDR criteria, as defi ned above, are given in Table 3 . Although the fi rst criteria tested (FEV 1 post-bronchodilator Ͻ80% predicted and FEV 1 /FVC ratio Ͻ70%) proved to be the most sensitive (100%) to diagnose COPD, it was the least specifi c (38%) criteria to rule out asthma. The second (BDR Ͻ 12% and FEV 1 absolute change Ͻ200 mL) and third (FEV1 change from predicted Ͻ9%) criteria had a specifi city of 81% and 76% respectively with a sensitivity of 55% and 59% respectively.
Discussion
Although previous studies have examined the ability of different BDR indices to distinguish between COPD and asthma, the diagnostic value of the post-bronchodilator FEV 1 / FVC ratio and FEV 1 Ͼ 80% predicted have to our knowledge not been assessed systematically in a group of obstructive lung disease patients with comparable baseline lung function severity. Our data suggest that the post-bronchodilator FEV 1 Ͼ 80% predicted in combination with a post-bronchodilator FEV 1 / FVC ratio Ͼ70% are more sensitive in diagnosing COPD, but it is less specifi c than the current ATS and ERS BDR indices (BDR Ͻ 12% and FEV 1 absolute change Ͻ200 mL or FEV1 change from predicted Ͻ9%) ( testing with reliable subjective measurements of dyspnea and quality of life has been found to be more sensitive to adequately predict a positive clinical response to bronchodilator therapy, but this comprehensive therapeutic assessment of bronchodilator effi cacy may not be feasible for many clinicians managing COPD (O'Donnell 2000) . An additional advantage of the FEV 1 /FVC fi xed ratio could be that only one post-bronchodilator fl ow volume curve is required, and the need for calculation of a BDR is eliminated, which means that this approach would be timesaving and less susceptible to calculation errors. It is known that the BDR is signifi cantly infl uenced by the degree of baseline impairment when expressed as a percentage of the initial fl ow volume curve value (Eliasson and Degraff 1985; . Despite the fact that patients with more severe obstruction will show a greater improvement than patients with a higher baseline value, this criteria is still used at times as part of the inclusion or exclusion criteria for pharmaceutical trials, and it can lead to inaccurate clinical diagnoses affecting patient management. Due to this well known fact we chose to include only patients with comparable baseline lung function impairment. This inclusion criterion resulted in relatively low numbers of patients ultimately included in the fi nal analysis and this could be a possible limitation of our study.
Instead of looking at degrees of reversibility that exceed arbitrary thresholds, a more useful feature for confi rmation of COPD is that the patient's lung function does not return to normal after bronchodilator administration (Calverley and Walker) . Unfortunately when applying the GOLD criteria in our group of obstructive lung disease patients 62% of the asthma patients fulfi lled the diagnosis for COPD purely on spirometric grounds. It is a well known fact that a percentage of patients with chronic severe asthma have persistent airfl ow obstruction (Bumbacea et al 2003) .
In our study population, there was a signifi cantly greater improvement in FEF 50 in the asthma group compared to the COPD group (Table 2 ). This sensitive parameter may be useful for long term studies in individuals when onset of disease is sought (Cochrane et al 1977) . It is, however, not recommended for routine assessment of the BDR due to intra-individual variability (Knudson et al 1983) .
Despite the inherent interdependence of FEV 1 and FVC, we found a differential response of the FEV 1 /FVC ratio between the two groups (Figure 1 ). Due to a greater FEV 1 compared to FVC response in the asthma group (Table 2) the FEV 1 /FVC ratio signifi cantly (p = 0.003) increased in the asthma group, but remained low in the COPD group after bronchodilatation. On close examination of previously published results it is interesting to note that the FVC response appears to be generally greater than the FEV 1 response in COPD patients, but the inclusion criteria for these studies varied considerably, and no mention is made of the signifi cance of the differences observed Newton et al 2002) . The choice of lung function tests for a given purpose should take into consideration the degree of variability of that test if the interpretation is not to be misleading (McCarthy et al 1975) . Tweeddale and colleagues (1987) found that the increase in FEV 1 and FVC that excluded natural variability with 95% confi dence in patients with obstructive ventilatory defects was 160 mL and 330 mL respectively. Whether these values are applicable for both COPD and asthma was not specifi ed in that study. Despite this inherent difference between these two lung function parameters, the ATS guidelines suggest an increase after bronchodilator administration of more than 200 mL in either FEV 1 or FVC to be signifi cant which may lead to diagnostic misclassifi cation (American Thoracic Society 1991).
The post-bronchodilator FEV 1 Ͼ 80% predicted parameter has the disadvantage of requiring a set of predicted values applicable to a specifi c population group, making comparison of international studies diffi cult. Using a fi xed percentage of the predicted value as the lower limit of normal can therefore result in inappropriate classifi cation of patients (Quedrelli et al 1999a) .
Using a fi xed FEV 1 /FVC ratio as the lower limit of normal has recognized limitations (Knudson et al 1983; American Thoracic Society 1991) . It has, however, been suggested by some authors to offer certain benefi ts as a compromise solution among competing defi nitions of obstruction, in that the fi xed ratio is easy to remember and does not require the use of population specifi c reference tables (Celli et al 2003) . This assumption remains to be verifi ed in large population based studies. It cannot be emphasized enough that no single spirometric parameter or index will take the place of clinical evaluation in diagnosing patients with COPD or asthma, but spirometry is supplementary and remains the objective cornerstone (Pauwels et al 2001) . Agreement should be reached internationally on the spirometric evaluation of patients with obstructive lung disease. Different criteria used to defi ne obstruction and reversibility will result in vastly different prevalence rates of obstructive lung diseases in the general population and it complicates international comparisons of studies (Viegi et al 2000; Celli et al 2003) . It is time that the appropriateness of defi nitions used to date is reconsidered.
The lung function data for each patient on our study can be seen as a snap shot and longitudinal reevaluation would have been ideal. Fluctuation in airway function is a well known fact, and it has to be taken into account in the evaluation of patients that the lungs are a complex and dynamic system. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD (Chhabra 2005) . It does not help that the guidelines focuses on post bronchodilator FEV 1 for COPD and pre bronchodilator values for asthma when it comes to classifi cation of disease severity (Sterk 2004) .
In an attempt to keep the groups clinically diagnosed with COPD or asthma as "pure" as possible, we did not include asthmatic smokers, patients with known combined disease or patients with COPD in the absence of a strong smoking history. The selection criteria of COPD and asthma patients could therefore potentially be seen as artifi cial. All of these groups would warrant special attention in clinical practice, but for the purposes of the article it was impossible to include them. In our study population the post-bronchodilator FEV 1 Ͻ 80% predicted in combination with the FEV 1 /FVC ratio value Ͼ70% (criteria #1) was very sensitive (100%) in diagnosing COPD. Unfortunately the criteria were unable to distinguish reliably between patients with COPD and asthma as 62% of asthmatic patients did not achieve "normal" spirometry in the stage of obstructive lung disease studied here. The conventional BDR criteria (criteria #2 FEV 1 Ͻ 12% and absolute change Ͻ200 mL, criteria #3 FEV 1 change from predicted Ͻ9%) were specifi c, because a smaller percentage of asthma patients fell below the historically selected positive BDR response criteria, but it was less sensitive due to the positive BDR response in the COPD patients as well. It might be a good idea to combine the GOLD criteria (criteria #1) as well as the conventional BDR criteria (criteria #2) to increase the accuracy. In summary, asthmatic subjects show more reversibility than COPD subjects even when they have post-BD airfl ow obstruction. Adding the bronchodilator test in the diagnoses of COPD (GOLD) guidelines could help to reduce the misclassifi cation of asthmatics with COPD.
In the evaluation of obstructive lung disease spirometry remains an investigative tool to confi rm a clinical suspicion. Additional meaningful outcome measures are urgently needed to accurately distinguish between COPD and asthma.
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